Drug Trial Radar · NCT07951632
Allogeneic iNKT Cells in AS: Immune Remodeling Study
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Apr 16, 2028
Study completion Apr 16, 2028
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study observes patients with ankylosing spondylitis (AS) who are receiving, or have received, multiple infusions of allogeneic invariant natural killer T (iNKT) cells as a treatment. Allogeneic iNKT cells are immune cells taken from a healthy donor, grown in the laboratory, and given to patients by infusion. The treatment infusions are given under a separate treatment protocol. This study does not give any treatment. It only collects blood samples and analyzes them to learn how the immune system changes during and after the cell infusions. Researchers will study two main questions: (1) how iNKT cell subsets and the overall immune cell network in the blood change over time, and (2) what the iNKT cells look like at the single-cell level, including their transcriptional (gene expression) profiles and clonal evolution.. Participants will provide blood samples at scheduled study visits for up to 52 weeks. The goal is to better understand how allogeneic iNKT cell therapy reshapes the immune system in AS, which may help guide future treatment studies.
Conditions
- Ankylosing Spondylitis
Interventions
Allogeneic iNKT CellsBiological
Ex vivo expanded allogeneic invariant natural killer T (iNKT) cells administered by infusion under a separate treatment protocol. This study observes participants receiving this treatment; infusions are not administered by this observational study. Data collected include peripheral blood immune cell phenotyping and single-cell transcriptomic analysis to assess immune remodeling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Peripheral Blood iNKT Cell Subset Polarization During Multiple Infusions of Allogeneic iNKT CellsTime frame: Up to 52 weeks
- Change in Peripheral Blood Immune Network Remodeling During Multiple Infusions of Allogeneic iNKT CellsTime frame: Up to 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.